Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 25;316(6):250.
doi: 10.1007/s00403-024-03109-7.

A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA's adverse events reporting system

Philippe Jean-Pierre  1 , Keyvan Nouri  2
Affiliations

A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA's adverse events reporting system

Philippe Jean-Pierre et al. Arch Dermatol Res. .

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer arising from squamous cells of the epidermis. Most cases of cSCC have a good prognosis if detected and treated early; however, certain cases can be aggressive. The primary risk factor for cSCC is prolonged ultraviolet radiation from sun exposure, leading to DNA mutations. Other risk factors have also been observed, including adverse reactions to medications, particularly immunosuppressants. A query of the Food and Drug Administration Adverse Events Reporting System (FAERS) was done, and all reported events of cSCC as adverse events to medication were recorded along with demographic data of patients affected. A total of 4,792 cases of cSCC as an adverse event to medication were reported between 1997 and 2023. Lenalidomide, a chemotherapeutic drug, had the most cases of cSCC as an adverse event. Nine of the top 10 drugs associated with cSCC had immunosuppressive characteristics. While males had higher odds of cSCC associated with corticosteroids and calcineurin inhibitors, females had higher odds of cSCC related to monoclonal antibodies. Geriatric patients accounted for the majority of cSCC cases at 59.7%. Drawing on data from the FAERS database, there's been a consistent increase in cSCC cases as a side-effect to certain medications, with most having immunosuppressive characteristics. Since there is a lack of up-to-date literature overviewing the most implicated medications for cSCC, we aimed to illustrate this better, as well as patient demographics, to better guide clinicians when prescribing these medications.

Keywords: Adverse events; Clinical research; Drugs; General dermatology; Medications; Side-effects; Skin cancer; Squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Reported cases of cutaneous squamous cell carcinoma as an adverse event
Fig. 2
Fig. 2
The top 20 medications associated with cutaneous squamous cell carcinoma as an adverse event
Fig. 3
Fig. 3
Reported cases of cutaneous squamous cell carcinoma by patient sex
Fig. 4
Fig. 4
Reported cases of cutaneous squamous cell carcinoma by patient age group
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(2):237–247. doi: 10.1016/j.jaad.2017.08.059. - DOI - PubMed
    1. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence Estimate of Nonmelanoma skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012. JAMA Dermatol. 2015;151(10):1081. doi: 10.1001/jamadermatol.2015.1187. - DOI - PubMed
    1. Dreyfuss I, Kamath P, Frech F, Hernandez L, Nouri K (2022) Squamous cell carcinoma: 2021 updated review of treatment. Dermatol Ther 35(4). 10.1111/dth.15308 - PubMed
    1. Wikonkal NM, Brash DE. Ultraviolet Radiation Induced signature mutations in Photocarcinogenesis. J Invest Dermatology Symp Proc. 1999;4(1):6–10. doi: 10.1038/sj.jidsp.5640173. - DOI - PubMed
    1. Yuspa SH. Cutaneous chemical carcinogenesis. J Am Acad Dermatol. 1986;15(5):1031–1044. doi: 10.1016/S0190-9622(86)70267-3. - DOI - PubMed

MeSH terms